Altis Biosystems has developed a patent-pending stem cell platform, which recreates both the small and large human intestinal epithelium for drug testing and microbiome research. Altis' market is to assist pharmaceutical and biotechnology companies in reducing the cost and time of drug development by providing a platform that more closely replicates the human body’s native biology. This should also reduce the need for animal testing.